Zinc compound paste
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 2 · 1992–2026
Showing the 50 most relevant studies, sorted by most relevant.
Calvin C. Willhite, Nataliya A. Karyakina, Robert A. Yokel, et al.
Critical Reviews in Toxicology, 2014
- Aluminum
- Aluminum Hydroxide
- Aluminum Oxide
Rongfeng Li, Hui Qi, Yuan Ma, et al.
Nature Communications, 2020
- Equipment Design
- Nitric Oxide
- Biosensing Techniques
A. Youssef, S. El-sayed, H. El-Sayed, et al.
Carbohydrate polymers, 2016
Chengzhi Hu, Salvador Pané, Bradley J. Nelson
Annual Review of Control Robotics and Autonomous Systems, 2018
Prescott D, Stewart A, Schoep A, et al.
2026
- Pruritus
- Dog Diseases
- Zinc
ObjectivesTo assess the efficacy of an essential oil, salicylic acid and zinc-based cream in the relief of pruritus not secondary to infectious pyoderma or ectoparasites and associated dermatological lesions.MethodsForty-one client-owned, otherwise healthy, dogs with chronic, noninfectious pruritus were enrolled in a double-blinded, placebo-controlled, randomised clinical trial. Dogs were assigned to receive topical treatment using either the study or placebo cream daily for 14 days. Owners recorded pruritus scores using a visual scale (Pruritus Analog Visual Scale [PVAS]) in a daily diary. Severity of skin lesions was quantified before and after the trial using the Canine Atopic Dermatitis Extent and Severity Index - 4th Generation (CADESI-4) rubric. Baseline and post-trial blood counts and serum biochemistries were used to assess health and screen for any evidence of toxicity secondary to cream application.ResultsFourteen-day course of treatment with the study cream was associated with 1.75x greater reduction in pruritus score compared to placebo. The reduction in pruritus was greater in the treatment versus placebo groups starting at day 9 of treatment and continued through day 14. Visible skin lesions improved with treatment but did not improve with placebo. Quality of life scores improved in both groups, but improvement was greater in the treatment group.Clinical significanceThe topical cream used in this study was a safe and effectives complementary treatment for the relief of pruritus and dermatological lesions in dogs.
Abstract licence: CC BY
Kenneth Markowitz, Michael R Moynihan, Mintsai Liu, et al.
Oral Surgery Oral Medicine Oral Pathology, 1992
- Biocompatible Materials
- Dental Pulp
- Eugenol
Andrzej Leonowicz, Anna Matuszewska, Jolanta Luterek, et al.
Fungal Genetics and Biology, 1999
N. Herawati *, , S. Suzuki, K. Hayashi, I. F. Rivai
Bulletin of Environmental Contamination and Toxicology, 2000
Frank M. Biro, Robert P. McMahon, Ruth Striegel-Moore, et al.
The Journal of Pediatrics, 2001
Sameh Samir Ali, Reda Morsy, Nessma A. El-Zawawy, et al.
International Journal of Nanomedicine, 2017
- Anti-Infective Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Burns
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.